MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
APVO — Aptevo Therapeutics Inc
NasdaqAptevo Therapeutics Inc
$1.76
+0.00(+0.00%)
- O
- 1.80
- H
- 1.80
- L
- 1.76
- V
- 11.89K
⏱️ End-of-day dataAs of Oct 2, 2026
Aptevo Therapeutics Inc Statistics
Total Valuation
| Market Cap | $3.42M |
| Enterprise Value | -$7.57M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | 1.81M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.27 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 1.13 |
| EV / Sales | n/a |
| EV / EBITDA | 1.11 |
| EV / EBIT | 1.11 |
| EV / FCF | 0.95 |
Financial Position
| Current Ratio | 3.36 |
| Quick Ratio | n/a |
| Debt / Equity | 0.30 |
| Debt / EBITDA | -0.52 |
| Debt / FCF | -0.44 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | -57.67% |
| Return on Assets (ROA) | -33.65% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-202,939 |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | -93.26% |
| 50-Day Moving Average | $2.70 |
| 200-Day Moving Average | $5.46 |
| Relative Strength Index (RSI) | 46.77 |
| Average Volume (20 Days) | 75,073 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -$6.84M |
| Pretax Income | -$6.70M |
| Net Income | -$6.70M |
| EBITDA | -$6.80M |
| EBIT | -$6.84M |
| Loss Per Share | $-6.41 |
Balance Sheet
| Cash & Cash Equivalents | $14.52M |
| Total Debt | $3.53M |
| Net Cash | $10.99M |
| Net Cash Per Share | $6.07 |
| Equity (Book Value) | $11.61M |
| Book Value Per Share | $6.41 |
| Working Capital | $11.22M |
Cash Flow
| Operating Cash Flow | -$6.67M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -$7.96M |
| FCF Per Share | $-4.40 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | -232.81% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |